康旗股份(300061.SZ):費錚翔減持期過半 協議轉讓事項正辦理中
格隆匯12月3日丨康旗股份(300061.SZ)公佈,公司分別於2019年9月6日和2019年10月12日披露了《關於持股5%以上股東協議轉讓公司股份的提示性公告》、《關於持股5%以上股東簽署協議轉讓部分公司股份之補充協議的公告》,費錚翔擬以協議轉讓方式向南平盈捷企業管理合夥企業(有限合夥)(“南平盈捷”)轉讓其持有的公司約3976.12萬股無限售條件流通股,佔公司總股本的5.87%,佔剔除回購專用賬户中的股份後公司總股本的6.00%。
截至目前,減持公司股份計劃時間已過半,費錚翔正在以協議轉讓方式實施此次減持計劃,協議轉讓正在辦理過程中。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.